Press-release for stocks related to als

Prices are updated after-hours

tags : Als

save search

Todays' Top-5
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
NRSN | News | $2.5 47.06% 0.0% |

| 48.81% | O: 54.76% H: 26.92% C: -3.85%
als therapeutics positive results

Sally Frykman, CMO von Velodyne Lidar, wurde als Finalistin für den Sensors Converge Award nominiert
Published: 2022-06-11 (Crawled : 17:00) - velodynelidar.com
VLDR S | $1.125 -8.54% 0.81% |

Electronic Technology

| Email alert Add to watchlist
FNCTF | News | $11.38 |

Communications

| Email alert Add to watchlist
cmo als

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALSManaged Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022
Published: 2022-06-16 (Crawled : 14:00) - biospace.com/
CYTK | $48.93 3.56% 0.0% |

Health Technology

| 19.0% | O: -2.48% H: 0.0% C: 0.0%
trials for extension als program

Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
AMLX | $19.94 6.57% 4.97% |

| 47.3% | O: -3.25% H: 15.66% C: -0.69%
treatment for canada health als approval

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium
Published: 2022-06-08 (Crawled : 12:00) - biospace.com/
MITO | News | $0.2674 -4.16% 0.36% |

Health Technology

| 12.78% | O: 58.35% H: 11.2% C: -14.06%
sbt-272 disease als symposium

Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
Published: 2022-06-03 (Crawled : 12:20) - biospace.com/
AMLX | $19.94 6.57% 4.97% |

| 103.99% | O: 36.13% H: 4.81% C: -7.14%
amx0035 treatment pdufa for als

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC
Published: 2022-06-01 (Crawled : 13:00) - biospace.com/
NRSN | News | $2.5 47.06% 0.0% |

| 77.3% | O: 8.48% H: 1.33% C: -8.47%
primec for als trial therapy

Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
Published: 2022-05-26 (Crawled : 17:00) - biospace.com/
AMLX | $19.94 6.57% 4.97% |

| 132.56% | O: -0.58% H: 0.0% C: -7.98%
als trial presentation results

NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022
Published: 2022-05-23 (Crawled : 13:20) - biospace.com/
NRSN | News | $2.5 47.06% 0.0% |

| 77.3% | O: -4.96% H: 8.96% C: 1.49%
drug als therapeutics

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
VYGR P | $5.95 3.3% -5.56% |

Health Technology

| -7.76% | O: -1.86% H: 3.8% C: 0.95%
preclinical als therapy results pre-clinical

Neuvivo Begins Manufacturing of NP001 for Treatment of ALS
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
TMO | $543.64 -0.22% 0.05% |

Health Technology

| 3.31% | O: -0.88% H: 0.0% C: 0.0%
np001 treatment for als

Amylyx Augments Case for ALS Drug Ahead of PDUFA Date
Published: 2022-05-05 (Crawled : 22:00) - biospace.com/
CLNN | News P | $3.09 6.55% -13.79% |

| -1.27% | O: 0.0% H: 0.32% C: -7.96%
drug pdufa for als

Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
Published: 2022-05-05 (Crawled : 18:00) - biospace.com/
AMLX | $19.94 6.57% 4.97% |

| 96.94% | O: -0.79% H: 1.1% C: -7.57%
amx0035 als trial publication

Denali/Sanofi ALS Candidate Hits Phase II as Awareness Month Begins
Published: 2022-05-03 (Crawled : 15:00) - biospace.com/
SNY | News | $52.62 -1.5% -0.41% |

Health Technology

| -0.33% | O: 1.21% H: 0.0% C: 0.0%
als

Environmental Testing Market Size to Grow by USD 3.79 Billion | Alpha Analytical Inc., ALS Ltd., and American Environmental Testing Laboratory LLC Emerge as Dominant Players | Technavio
Published: 2022-05-03 (Crawled : 01:00) - prnewswire.com
IKTSY | News | $53.0 |

Professional, Scientific, and T...

| -13.07% | O: 1.6% H: 1.26% C: 1.07%
als market test

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
Published: 2022-05-02 (Crawled : 13:00) - biospace.com/
SNY | News | $52.62 -1.5% -0.41% |

Health Technology

| -2.38% | O: -2.05% H: 0.0% C: 0.0%
DNLI D | $30.75 -0.58% 3.46% |

Health Technology

| 21.93% | O: -6.34% H: 6.77% C: 6.48%
SNYNF | News | $104.5 |

Health Technology

| 3.41% | O: 0.08% H: 0.0% C: 0.0%
for als trial therapeutics sanofi milestone

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
Published: 2022-04-25 (Crawled : 13:00) - biospace.com/
WVE | $2.66 -5.67% -1.42% |

Health Technology

| 42.25% | O: 2.67% H: 7.81% C: 5.21%
wve-004 preclinical for als publication pre-clinical

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS
Published: 2022-04-11 (Crawled : 13:20) - biospace.com/
NRSN | News | $2.5 47.06% 0.0% |

| -11.66% | O: -2.12% H: 0.72% C: -13.72%
primec for als therapeutics enroll

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
Published: 2022-04-06 (Crawled : 14:00) - biospace.com/
NRSN | News | $2.5 47.06% 0.0% |